Coronavirus Notebook: Valneva Vaccine To Begin EU Rolling Review, Synairgen Reports Progress With Inhaled IFN-Beta
The European Parliament is pushing for more of a say in how Europe’s new emergency response authority, HERA, deals with R&D and procurement of vaccines and therapies in times of health crises. NRx Therapeutics says it will continue to seek US approval of aviptadil for COVID-19.
You may also be interested in...
Europe is stepping up its efforts to prepare for future health crises. A new parliamentary committee will look at how to make the most of the lessons learned from the coronavirus pandemic, while EU health ministers will next week discuss “vaccine solidarity” and the draft regulation on cross-border threats to health.
COVID-19, resource constraints and a forthcoming expansion of its responsibilities are piling the pressure on the EU regulator.
NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.